After grabbing 12881.0 shares, the institutional investor is now in possession of 12881.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 0.14% having worth around $52039.0. Moreover, Royal Alliance Associates, Inc. (.. increased its share by 1000.0 to have a control over 1000.0 shares. And Private Advisor Group LLC raised its holdings to 104.0 shares by acquiring 104.0 shares or 0.00% of the stake.
Hepion Pharmaceuticals Inc. (HEPA) concluded trading on 08/27/20 at a closing price of $3.53, with 1.23 million shares of worth about $4.35 million changed hands on the day. Weekly performance of the stock remained negative as price took a plunge of -7.35% during that period and on Thursday the price saw a gain of about 0.86%. Currently the company’s common shares owned by public are about 8.50M shares, out of which, 6.07M shares are available for trading.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 2 analysts are covering the HEPA stock and their offered price forecasts bring an average price target of $13.00. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $14.00 and could fall to a lowest price of $12.00. Analysts also issued an outlook of 2.00 for the Hepion Pharmaceuticals Inc. stock for next 12 months. However, touching the estimated high of $14.00 would mean a gain of 74.79% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 0 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
DFA US Micro Cap Portfolio, DFA US Targeted Value Portfolio, and Vanguard Extended Market Index Fu are the top 3 mutual funds which are holding stakes in Hepion Pharmaceuticals Inc. DFA US Micro Cap Portfolio is currently holding 11778.0 shares of worth totaling $47583.0. The company recently came buying 9560.0 shares which brought its stake up to 0.13% of the company’s outstanding shares. DFA US Targeted Value Portfolio bought 3400.0 shares, after which its hold over company’s outstanding shares expand to 0.13%, leaving 11338.0 shares with the mutual fund that have a worth of about $45806.0. Vanguard Extended Market Index Fu, after buying 1446.0 shares, have now control over 0.02% of the stake in the company. It holds 0.0 shares of worth $5842.0.
Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) started trading at $3.55, above $0.05 from concluding price of the previous day. However, the stock finished the trading on the day at a closing price of $3.53, or with a gain of 0.86%. Stock saw a price change of -7.35% in past 5 days and over the past one month there was a price change of -15.95%. Year-to-date (YTD), HEPA shares are showing a performance of -34.14% which increased to 46.47% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.00 but also hit the highest price of $8.35 during that period. While comparing its average daily trading volume of 1.68 million shares, we see that about 1.23 million changed hands on the day. The stock is currently trading -11.06% below its 20-day simple moving average (SMA20), while that difference is down -1.81% for SMA50 and it goes to 3.20% higher than SMA200.
Squarepoint OPS LLC acquired 12881.0 shares of Hepion Pharmaceuticals Inc. having value of about $52039.0. Hepion Pharmaceuticals Inc. (NASDAQ: HEPA) currently have 8.50M outstanding shares and institutions hold larger chunk of about 3.60% of that. Holding of mutual funds in the company is about 0.28% while other institutional holders and individual stake holders have control over 1.28% and 0.01% of the stake respectively.
The stock has a current market capitalization of $31.63M and its 3Y-monthly beta is at 1.90. It has posted earnings per share of -$2.61 in the same period. It has Quick Ratio of 7.00 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for HEPA, volatility over the week remained 7.43% while standing at 7.16% over the month.
Analysts are in expectations that Hepion Pharmaceuticals Inc. (HEPA) stock would likely to be making an EPS of -$0.48 in the current quarter, while forecast for next quarter ESPS is -$0.37 and it is -$1.21 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.5 which is -$0.47 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 93.70% while it is estimated to decrease by -181.00% in next year.
Analysts at 2 brokerage firms have issued recommendations for the Hepion Pharmaceuticals Inc. (HEPA)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 2 Wall Street analysts, 2 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by ROTH Capital on July 20, 2020 offering a Buy rating for the stock and assigned a target price of $14 to it.